Epix Pharmaceuticals Inc is going to stop further development of its depression drug, which failed to show sufficient effectiveness in a recent mid-stage trial, sending its shares down 32 percent.
While the drug, PRX-00023, showed a good safety and tolerability profile, the overall results of the trial were disappointing, Chief Executive Michael Kauffman said in a statement.
The drug, which was the most advanced in Epix's pipeline, had already failed to prove effective for general anxiety disorder in 2006, following which the company investigated it as a treatment for major depressive disorder.
Epix has other compounds in its pipeline that it is investigating as treatments for Alzheimer's disease and pulmonary blood pressure.
Epix sells Vasovist, an imaging agent, outside the United States. The company is awaiting U.S. approval for the product and is still struggling with regulatory obstacles.
It plans to refile a marketing application with the U.S. Food and Drug Administration in mid-2008.
Shares of the company were trading at $2.10 before the bell. They closed at $3.08 Wednesday on Nasdaq.
The discovery of the submarine has unveiled a few "inconsistencies." For example, how can one explain the fact that the sub was found where it needed to be searched for from the start?
When on a state visit to Singapore, Russian President Vladimir Putin promised to revisit the discussion of the 1956 Declaration between the USSR and Japan regarding the issue of the peace treaty with Japan
The TurkStream, which runs along the bottom of the Black Sea from Russia's Anapa to Turkey, will consist of two lines, each with a capacity of 15.75 billion cubic meters of gas a year